Highlights

  • Island Pharmaceuticals shares rose 2.86% on 10 June 2026 following an update on its Galidesivir development program.
  • The company executed an expanded CRADA agreement with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation.
  • The amended agreement finalises study design and resourcing requirements for a planned Galidesivir dose optimisation study targeting Marburg Virus Disease.
  • The study is expected to commence next quarter, with topline results anticipated in the second half of CY26.

Island Pharmaceuticals Ltd (ASX:ILA) shares gained 2.86% to AUD 0.36 during the morning Trading session on 10 June 2026 after the company announced an expansion of its existing Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation. The update advances Island's Galidesivir program and clears the way for a planned dose optimisation study focused on Marburg Virus Disease (MVD).

The latest development appears to have attracted investor attention as it represents a significant operational step for the company's planned FDA Animal Rule pathway. While today's rise was modest, Island Pharmaceuticals has delivered a considerably stronger longer-term performance, with the stock remaining up 89.47% over the past year.

About Island Pharmaceuticals

Island Pharmaceuticals is an Australian antiviral Drug Development company focused on diseases that present significant public health, biosecurity and infectious disease challenges. The company is advancing two key Assets within its development portfolio: ISLA-101 and Galidesivir.

ISLA-101 is being developed for the prevention and treatment of dengue fever and other mosquito-borne diseases, while Galidesivir is a clinical-stage broad-spectrum antiviral candidate with activity demonstrated across more than 20 RNA viruses. These include several high-priority pathogens such as Ebola, Marburg, Middle East Respiratory Syndrome (MERS), Zika virus and Yellow Fever.

The company's development strategy is centred on addressing diseases where treatment Options remain limited and where governments and public health agencies continue to seek medical countermeasures against emerging viral threats.

Expanded Agreement Advances Galidesivir Development Program

The primary focus of the announcement was the expansion of Island's existing CRADA with USAMRIID and The Geneva Foundation.

According to the company, the amended agreement finalises the design and operational requirements necessary to commence a planned dose optimisation study evaluating Galidesivir as a potential treatment for Marburg Virus Disease.

The expanded agreement enables Island to utilise USAMRIID's Biosafety Level 4 (BSL-4) containment facilities for the study. These facilities are designed for research involving highly hazardous pathogens and are among the most specialised infectious disease research environments available.

Management stated that the updated CRADA resolves the remaining study design and resource planning requirements, allowing the program to proceed according to schedule.

The agreement also supports the company's broader two-stage development strategy under the FDA Animal Rule framework, which Island has previously outlined as a pathway for advancing Galidesivir toward potential regulatory approval.

Why USAMRIID Plays an Important Role

USAMRIID occupies a unique position within infectious disease and biodefence research.

The institute serves as the United States Army's primary research Facility for studying highly hazardous biological agents and is the only Department of War laboratory equipped with Biosafety Level 4 containment capabilities.

For more than five decades, USAMRIID has conducted research aimed at developing vaccines, therapeutics, diagnostics and countermeasures against biological threats that may impact both military personnel and civilian populations.

The institute has also played a role in Galidesivir's historical development, contributing to preclinical and non-human primate studies that evaluated the antiviral candidate against viruses including Ebola and Marburg.

By expanding its collaboration with USAMRIID, Island strengthens its access to specialised facilities, scientific expertise and operational infrastructure required for advanced infectious disease studies.

Dose Optimisation Study Designed to Refine Future Development

The planned study will focus on determining the minimally effective dose of Galidesivir against the Angola strain of Marburg virus.

According to the study design outlined by the company, researchers will evaluate multiple dosing regimens as well as different treatment initiation timelines following viral exposure.

Treatment is expected to begin either 24 hours or 48 hours after exposure to the Marburg Angola strain. Galidesivir will then be administered intravenously twice daily over a 14-day treatment period.

The primary endpoint of the study will assess survival through 28 days following exposure. Researchers will also evaluate a range of additional parameters including clinical signs of disease, viral load measurements, pharmacokinetic data and clinical pathology indicators.

The study protocol includes comprehensive laboratory assessments such as RT-PCR testing, plaque assays, hematology analysis, serum chemistry, coagulation testing and full histopathological evaluation.

Island believes the study will generate critical information regarding dose selection and treatment effectiveness that can support future stages of development.

Previous Study Results Provide Foundation for Current Program

The upcoming study builds upon previously reported non-human primate data evaluating Galidesivir against Marburg virus infection.

According to Island, earlier studies demonstrated approximately 94% survival among Galidesivir-treated animals infected with the Marburg Musoke strain. In comparison, placebo-treated control groups recorded 0% survival.

These findings formed part of the scientific foundation supporting the continued development of Galidesivir and contributed to the company's decision to pursue further efficacy studies.

The planned dose optimisation program seeks to build on those earlier findings by generating additional data specific to the Marburg Angola strain while also helping determine appropriate dosing strategies for future studies.

Management noted that the new study is intended to provide efficacy, pharmacokinetic and translational information that will assist in planning a subsequent pivotal efficacy study.

Supporting the FDA Animal Rule Development Pathway

A key objective of the upcoming study is to support Island's broader regulatory strategy.

The company is pursuing development of Galidesivir under the FDA Animal Rule pathway, which provides a potential approval route for certain treatments targeting diseases where conventional human efficacy trials may not be feasible or ethical.

Under this framework, efficacy can be demonstrated through appropriate animal studies when supported by additional scientific and clinical evidence.

Island has indicated that the dose optimisation study will provide data intended to support the design of a future pivotal confirmatory efficacy study, which forms an important component of the Animal Rule process.

The company views the current study as an important step toward generating the information required for later-stage regulatory discussions.

Operational Preparation Underway Ahead of Study Launch

While dosing activities are expected to run for approximately 30 days, the company noted that studies conducted within Biosafety Level 4 environments require extensive planning and preparation.

Island is currently working with USAMRIID and The Geneva Foundation on final operational readiness activities ahead of the study's commencement.

The company expects the study to begin next quarter, with topline results anticipated during the second half of calendar year 2026.

Following completion of the dose optimisation work, Island intends to utilise the resulting data to inform the design of a subsequent pivotal efficacy study.

The company also stated that it continues discussions with additional Biosafety Level 4 facilities while pursuing broader regulatory, scientific and biodefence engagement initiatives.

Broader Biodefence Engagement Continues

Beyond the immediate study program, Island continues to pursue opportunities related to biodefence and medical countermeasure development.

The company disclosed that it remains engaged with US government Stakeholders and is evaluating potential future procurement and stockpiling opportunities.

Management also highlighted ongoing efforts to strengthen relationships within the biodefence sector while advancing discussions involving additional high-containment research facilities.

These activities form part of the company's wider strategy to position Galidesivir within areas where antiviral countermeasures may be required for emerging infectious disease threats.

An investor webinar has also been scheduled for 12 June 2026, during which management plans to provide additional insight into the expanded CRADA agreement, broader biodefence initiatives and opportunities relating to Ebola and Sudan virus programs.

What This Means for Investors

Island Pharmaceuticals' latest announcement represents an operational milestone for its Galidesivir development program. The expanded CRADA with USAMRIID and The Geneva Foundation finalises the framework needed to commence a planned dose optimisation study targeting Marburg Virus Disease.

The agreement provides access to specialised Biosafety Level 4 facilities and supports Island's planned progression under the FDA Animal Rule pathway. The upcoming study, expected to begin next quarter, is designed to generate efficacy, pharmacokinetic and dose optimisation data that may assist future development activities. The advancement of this program appears to have contributed to the positive share price reaction seen on 10 June 2026.